Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study)

INTRODUCTION: The COVID-19 pandemic has emerged worldwide. Although several medications have been approved for treating moderate-to-severe COVID-19, very few treatment strategy has been established for patients with mild COVID-19 who do not require oxygen administration. Clarithromycin is a macrolid...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Kazuko, Hosogaya, Naoki, Sakamoto, Noriho, Yoshida, Haruo, Ishii, Hiroshi, Yatera, Kazuhiro, Izumikawa, Koichi, Yanagihara, Katsunori, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458001/
https://www.ncbi.nlm.nih.gov/pubmed/34548368
http://dx.doi.org/10.1136/bmjopen-2021-053325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458001/
https://www.ncbi.nlm.nih.gov/pubmed/34548368
http://dx.doi.org/10.1136/bmjopen-2021-053325

Ejemplares similares